potent pan-PIM kinase inhibitor

oral PD and efficacy in xenograft model

from SBDD of prior lead

Bioorg. Med. Chem. Lett., Oct. 14, 2020

Sanofi, Waltham/Cambridge, MA

Structure of compound 27

“compound 27” (Sanofi oral in vivo pan-PIM kinase inhibitor)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: